Skip to content
Portfolio

Reactosome

Pre-seed

Instead of delivering just DNA or RNA, give cells an extra nucleus.

Today's gene therapies deliver one piece of genetic material at a time, which limits them to simple diseases. Reactosome builds synthetic cell components, an extra nucleus, that can act on many genes at once, opening nucleic acid therapies to complex diseases like solid cancers and age-related disorders.

Only a handful of scientists in the world can build a synthetic nucleus, and Reactosome is the one doing it for therapeutics. The company came through IndieBio and is backed by SOSV.

The memo is for Humain Ventures investors. You'll be asked to sign in.